Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

Autor:	E. Greinel, I. H. Gomolin, Jerry S. Wolinsky, Suhayl Dhib-Jalbut, David Ladkani, L. R. Rogers, J. Tamulevich, Yafit Stark, B. Gandhi, Staley A. Brod, J. B. Burns, Dennis L. Kolson, Sara G. Austin, K. A. McCarthy, J. W. Rose, S. J. Bird, E. Cerreta, J. H. Parnell, D. Lisak, Kenneth P. Johnson, S. Van Den Noort, L. Smith, L. Pardo, L. W. Myers, J. Guarnaccia, Hillel Panitch, G. W. Ellison, K. L. Conway, Jonathan Goldstein, Christopher T. Bever, C. C. Ford, Andrew D. Goodman, Timothy Vollmer, I. Pinchasi, OA Khan, G. R. Barger, J. W. Lindsey, S. L. Craig, F. J. Vriesendorp, A. Pruitt, B. R. Brooks, M. D. Petri, A. E. Miller, E. Katz, A. McKeon, J. Fleming, C. Kawai, Francisco Gonzalez-Scarano, C. Weasler, W. Mulcahy, A. B. Thomas, S. Reingold, L. P. Weiner, Cris S. Constantinescu, R. P. Lisak, N. Kachuck, D. Pfohl, R. W. Baumhefner, S. Kadosh, M. Dimachkie, D. Mellits
Rok vydání:	2000
Předmět:	medicine.medical_specialty Randomization business.industry Multiple sclerosis Copolymer I medicine.disease Placebo Confidence interval Surgery Subcutaneous injection Neurology Internal medicine Cohort medicine Neurology (clinical) Glatiramer acetate business medicine.drug
Zdroj:	Scopus-Elsevier
ISSN:	1477-0970 1352-4585
Popis:	In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone®) reduced the relapse rate and slowed accumulation of disability for patients with relapsing-remitting multiple sclerosis. Of the original 251 patients randomized to receive glatiramer acetate or placebo, 208 chose to continue in an open-label study with all patients receiving active drug. The majority of the original double-blind cohort continues to receive glatiramer acetate by daily subcutaneous injection and are evaluated at 6-month intervals and during suspected relapse. The data reported here are from approximately 6 years of organized evaluation, including the double-blind phase of up to 35 months and the open-label phase of over 36 months. Daily subcutaneous injections of 20 mg glatiramer acetate were well tolerated. The mean annual relapse rate of the patients who received glatiramer acetate since randomization and continued into the open-label study was 0.42 (95% confidence interval (CI), CI=0.34-0.51). The rat...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ced7b219d8e66817c7bc9a2e3e0fb2c9 https://doi.org/10.1191/135245800678827806 Zobrazit plný text záznamu